Emami Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2lfqj7y6g7s3jmh94r3d3vr8.pdf

Key Takeaways


Demand & Volume Reality

Mohan Goenka: "If the summer would have been favorable, then I'm sure the growth would have been very good."

Margin & Cost Structure

Mohan Goenka: "What is very, very heartening is that the input cost pressure has really eased and we are seeing margin expansion. So we would be able to put in some money on advertising on most of our categories."

Portfolio & Brand Health


Healthcare & Hospital Deal

Mohan Goenka: "The deal is signed, sealed, everything. We are just awaiting government approval. As soon as we get it, the transaction would conclude. It's just a matter of time. I think max of about 3 weeks to 4 weeks, that's what we think."

International & Start-up Bets

Vinod Nandgopal Rao: "We looked at potential, potential with respective in our categories, and we drove distribution in that manner. So that gave us a lot of confidence because we've got a very high repeat rate."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic business growth8-10% growth if trend continuesFY24
International business growthAt least 20% growthFY24
Healthcare business growth15-20% growthFY24
Start-up portfolio growthAt least 50-60% growthFY24
The Man Company profitabilityTurn profitableFY24
Gross margin expansion~150 bps expansionFY24
Core marginsMore than 27% if raw material easing continuesFY24
Advertising spend16.5-17% of revenueFY24
Tax rateSimilar to FY23; MAT credit utilization startsFY27
Hospital deal closureGovernment approval and transaction conclusionMax 3-4 weeks
Pledge reductionUpon hospital deal materializationContingent on deal

Key Metrics

MetricQ4 FY23
Revenue₹836 cr (per an analyst's math), +2% volume growth; Dermicool and The Man Company contributed ~10% to topline
Gross margin63.1%, expanded 60 bps YoY
EBITDA₹200 cr, +22% YoY; margin at 23.9%, expanded 260 bps YoY
EBITDA margin (ex-strategic investments)26.7% for FY23, close to pre-COVID levels
Profit before tax₹148 cr, +51% YoY
Profit before tax (FY23)₹670 cr, -3% YoY, +14% on 4-year CAGR basis
Domestic volume growth2% overall; organic volume growth was negative
International business growth+19% YoY in Q4, +20% in FY23
Modern trade growth+18% YoY
E-commerce growth+64% YoY
Modern trade and e-commerce saliency>20% of domestic sales, +500 bps YoY
Healthcare range growth-13% YoY in Q4, +8% on 4-year CAGR basis
Male grooming segment growth+29% YoY, primarily due to base impact
Advertising spend15.5% of net sales in FY23, down ~300 bps YoY; expected 16.5%-17% in FY24
Employee cost growth+16.8% YoY; ~10-11% excluding The Man Company integration
Other expenses growth+20% YoY; includes ~₹9-10 cr from The Man Company and distribution project costs
Impairment (Brillare Science)₹32 cr in standalone other expenses; ₹8-9 cr in consolidated intangible assets
Rural distribution reach52,000 towns and villages, up from 32,000 two years ago; added ~11,000 towns in FY23
Chemist coverage1.3 lakh chemists across India
The Man Company growth~40% in FY23; expected to be profitable in FY24
Domestic business growth guidance (FY24)8-10% expected, with ~3-3.5% from price increases
International business growth guidance (FY24)At least 20% expected
Healthcare business growth guidance (FY24)15-20% expected
Gross margin expansion expectation (FY24)~150 bps expansion expected